Aditxt, Inc. Enters Into Definitive Agreement To Acquire Evofem Biosciences For Consideration Of The Issuance Of A Combination Of Common Stock And Preferred Stock, And The Assumption Of Certain Senior Indebtedness, Having An Aggregate Amount Of ~$100M
Portfolio Pulse from Benzinga Newsdesk
Aditxt, Inc. (NASDAQ:ADTX) has entered into a definitive agreement to acquire Evofem Biosciences, Inc. (OTCQB:EVFM) for approximately $100 million, consisting of common and preferred stock issuance and assumption of senior indebtedness. Evofem's Phexxi, a non-hormonal contraceptive gel, has seen $13.4 million in net sales for the first nine months of 2023. The acquisition aims to expand into the global non-hormonal birth control market, projected to grow to $52.2 billion by 2031. The transaction is expected to close in the first half of 2024, subject to stockholder approvals and other conditions.
December 12, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aditxt's acquisition of Evofem could potentially enhance its product portfolio and market reach in the women's health sector, particularly in non-hormonal contraception.
The acquisition of Evofem positions Aditxt in a growing market, with the potential to increase revenue and market share. The positive sales figures and market projections for Phexxi could be seen as a strong addition to Aditxt's portfolio, likely leading to a positive short-term impact on ADTX's stock price.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Evofem's acquisition by Aditxt may provide the necessary resources and platform to scale Phexxi's market presence globally, benefiting shareholders and expanding women's health options.
Evofem's integration into Aditxt could lead to increased investment and market penetration for Phexxi, potentially resulting in a positive short-term impact on EVFM's stock price. The transaction also indicates a strategic move to enhance shareholder value and expand product offerings.
CONFIDENCE 70
IMPORTANCE 85
RELEVANCE 90